Else Nutrition

LUCIRA HEALTH (NASDAQ: LHDX) STOCK QUOTE

Last Trade: US$0.45
Volume: 0
5-Day Change: 223.07%
YTD Change: 307.11%
Market Cap: US$18.360M

LATEST NEWS FROM LUCIRA HEALTH

Lab-quality results for both COVID-19 and Flu now available at home from one single test COVID-19 and Flu have similar symptoms but different treatments, requiring a fast, differential test to access time-sensitive prescription treatment options Lucira’s COVID-19 & Flu Home Test demonstrated similar performance for COVID-19 and Flu in head-to-head comparison study with highly sensitive lab-based PCR tests Lucira also secured... Read More
GreenStockNews
Lab-quality results for both COVID-19 and Flu now available at home from one single test COVID-19 and Flu have similar symptoms but different treatments, requiring a fast, differential test to access time-sensitive prescription treatment options Lucira’s COVID-19 & Flu Home Test demonstrated similar performance for COVID-19,... Read More
EMERYVILLE, Calif., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Lucira Health, Inc. (Nasdaq: LHDX) (“Lucira Health,” “Lucira” or the “Company”), a medical technology company, announced today that it has filed for protection under Chapter 11 of the U.S. Bankruptcy Code in the United States Bankruptcy Court for the District of Delaware. The Company further disclosed that it intends to pursue a sale of its business under Section 363 of... Read More
GreenStockNews
New partnership enables a free Sesame telehealth consultation with purchase of a Lucira at-home COVID-19 test, providing a full test-to-treat experience from the comfort of home, within two hours NEW YORK , Jan. 5, 2023 /PRNewswire/ -- Sesame , the company building a radically new healthcare system for uninsured Americans and... Read More
For $98 CAD Canadians will receive a free telehealth appointment included with purchase of a test Lucira Connect provides lab-quality at-home test-users a telehealth visit at no additional cost, enabling Test-to-Treatment within hours for only the cost of the test, excluding prescription costs. Lucira partners with Medi-Call to give users who test positive for Covid-19 or Flu the option to access a virtual telehealth... Read More
EMERYVILLE, Calif., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Lucira Health, Inc. (Nasdaq: LHDX) ("Lucira Health" or "Lucira"), a medical technology company, announced that it submitted an Emergency Use Authorization application to the FDA for OTC use of its simple, at-home molecular COVID-19 & Flu test. Lucira’s test for COVID-19 & Flu was granted Emergency Use Authorization for Point-of-Care (POC) use in a healthcare setting in... Read More
GreenStockNews
Lucira COVID-19 & Flu Test is the first and only combination over-the-counter (OTC) self-test with fast, molecular lab-quality results enabling mass testing of symptomatic residents, staff and visitors amid the aggressive COVID-19 and flu season in Canada. Lucira’s 99% accurate, differential molecular test can detect Influenza... Read More
GreenStockNews
PCR Lab-quality NAAT/molecular test for both COVID-19 and flu from 1 shallow nasal swab Positive result as quickly as 11 minutes, negative result in 30 minutes, allowing diagnosis during patient visit Equipment-free Lucira platform requires no capital investment or calibration and permits unlimited simultaneous testing... Read More
GreenStockNews
Digital health service offers Lucira lab-quality at-home test users a telehealth visit at no additional cost, enabling Test-to-Treatment within hours for only $29, excluding prescription costs Lucira partners with Pfizer to increase awareness of the high risk factors for severe COVID-19 and treatment options through the Lucira... Read More
EMERYVILLE, Calif., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Lucira Health, Inc. (Nasdaq: LHDX) ("Lucira Health," "Lucira" or the "Company"), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease tests, today reported financial results for the third quarter ended September 30, 2022 and provided business updates. Recent Highlights Achieved net revenue of... Read More
Lucira Health, Inc. (“Lucira Health” or “Lucira”), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease tests, and a digital health platform that will connect patients with providers, today announced that the company will report third quarter 2022 financial results on, Monday, November 14 th , 2022. Lucira’s management will host a conference call... Read More
Lucira Health, Inc. (Nasdaq: LHDX) (“Lucira Health” or “Lucira”), a medical technology company, today announced interim results of a pilot study to evaluate the performance of their combined Chlamydia trachomatis and Neisseria gonorrhoeae assays integrated into the instrument-free at-home Lucira molecular test platform. The development of these assays is supported by several grants from the National Institutes of Health with... Read More
Lucira Health, Inc. (“Lucira Health” or “Lucira”), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits, and a digital health platform that will connect patients with providers, today announced that the company will participate in the LifeSci Partners HealthTech Symposium on September 21 st , 2022, at 10:30am ET. A live and archived... Read More
Lucira Health, Inc. (“Lucira Health” or “Lucira”), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits, today announced that the company will participate in the Gilmartin Group Emerging Growth Company Showcase on August 31 st , 2022. Lucira’s management is scheduled to present virtually at the Inaugural Gilmartin Group Emerging Growth... Read More
Lucira Health, Inc. (Nasdaq: LHDX) ("Lucira Health," "Lucira" or the "Company"), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease tests, today reported financial results for the second quarter ended June 30, 2022 and provided business updates. Recent Highlights Achieved net revenue of $26.1 million for the second quarter of 2022, an increase of... Read More
GreenStockNews
Lucira Health, Inc. (Nasdaq: LHDX) ("Lucira Health," "Lucira" or the "Company"), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease tests, today announced that Health Canada has granted Authorization under Interim Order for the emergency use and... Read More
Lucira Health, Inc. (“Lucira Health” or “Lucira”), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits, today announced that the company will report second quarter 2022 financial results on, Monday, August 15, 2022. Lucira’s management will host a conference call and webcast at 1:30 p.m. PT / 4:30 p.m. ET that day to discuss the financial... Read More
Lucira Health, Inc. ("Lucira Health" or "Lucira") (Nasdaq: LHDX), a medical technology company focused on the development and commercialization of innovative infectious disease tests today announced that on July 27, 2022, the Board of Directors of Lucira granted inducement awards consisting of 1,051,405 restricted stock units (“RSUs”) under Lucira’s 2022 Inducement Plan. The Board of Directors approved the awards as an... Read More
Lucira Health, Inc. (Nasdaq: LHDX) (“Lucira Health,” “Lucira” or the “Company”), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease tests, today reported financial results and provided business updates for the first quarter ended March 31, 2022. Recent Highlights Achieved net revenue of $90.5 million for the first quarter of 2022, equivalent to... Read More
Lucira Health, Inc. ("Lucira Health" or "Lucira") (Nasdaq: LHDX), a medical technology company focused on the development and commercialization of innovative infectious disease tests, announced today that it has submitted a request to the U.S. Food and Drug Administration for emergency use authorization (EUA) for its COVID-19 & Flu test. The request is for prescription at-home use of the PCR-quality test for those with... Read More
GreenStockNews
Lucira Health , Inc. ("Lucira Health" or "Lucira") (Nasdaq: LHDX), a medical technology company focused on the development and commercialization of innovative infectious disease tests, announced that both its COVID-19 & Flu and COVID-19 molecular tests have received CE Mark for professional use, clearing both tests for sale... Read More
Lucira Health, Inc. (“Lucira Health” or “Lucira”), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits, today announced that the company will participate in the Bank of America 2022 Healthcare Conference on May 11th, 2022, at 11:00pm ET. Lucira’s management is scheduled to present at the Bank of America 2022 Healthcare Conference on May... Read More
Lucira Health, Inc. (“Lucira Health” or “Lucira”), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits, today announced that the company will report first quarter 2022 financial results on Thursday, May 12, 2022. Lucira’s management will host a conference call and webcast at 1:30 p.m. PT / 4:30 p.m. ET that day to discuss the financial... Read More
GreenStockNews
Lucira is the official COVID-19 test provider of USA Boxing athletes and staff and will commit $5 of support to the organization for each test purchased by fans Lucira Health, Inc. ("Lucira Health" or "Lucira") (Nasdaq: LHDX), a medical technology company focusing on the development and commercialization of transformative and... Read More
Lucira Health, Inc. (Nasdaq: LHDX), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits, today announced that on April 6, 2022, the Board of Directors of Lucira granted inducement awards consisting of 20,825 restricted stock units (“RSUs”) to three new employees under Lucira’s 2022 Inducement Plan. The Board of Directors approved the... Read More
GreenStockNews
COVID-19 Comes to Isolated Pacific Island of Tonga And Cases Soar After Volcanic Eruption and Tsunami Lucira Health, Inc. ("Lucira Health" or "Lucira") (Nasdaq: LHDX), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease tests, donated 2,000 Lucira ™... Read More
GreenStockNews
Lucira's molecular test provides PCR-quality results in 30 minutes in a simple single-use test Lucira was the first at-home COVID-19 test authorized in Canada and has been used in public health programs and for safe travel Lucira Health, Inc. ("Lucira Health" or "Lucira") (Nasdaq: LHDX), a medical technology company focused on... Read More
Lucira Health, Inc. (Nasdaq: LHDX) (“Lucira Health,” “Lucira” or the “Company”), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits, today reported financial results for the fourth quarter and full year ended December 31, 2021. Recent Highlights Achieved net revenue of $61.1 million for the fourth quarter of 2021, representing... Read More
Lucira Health, Inc. (“Lucira Health” or “Lucira”) (Nasdaq: LHDX), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits, today announced that the company will report fourth quarter 2021 financial results on, Thursday, March 10, 2022. Lucira’s management will host a conference call and webcast at 1:30 p.m. PT / 4:30 p.m. ET that day to... Read More
Lucira Health, Inc. ("Lucira Health" or "Lucira") (Nasdaq: LHDX), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits, today announced that on February 4, 2022, it entered into a debt facility of up to $80 million with Hercules Capital, Inc. (NYSE: HTGC) ("Hercules") and Silicon Valley Bank (NASDAQ: SIVB) ("SVB"). "This debt financing... Read More
Lucira Health, Inc. ("Lucira Health" or "Lucira") (Nasdaq: LHDX), a medical technology company focusing on the development and commercialization of transformative and innovative infectious disease test kits, announced more than two million Lucira ™ Check-It COVID-19 tests, a rapid at-home test with PCR-quality accuracy, are available on Amazon.com . Lucira's tests are available with 1-2 day Prime delivery nationwide.... Read More
Lucira's COVID-19 test is the only EUA authorized rapid at-home self-test that delivers PCR accuracy and early detectability in a single-use test kit with results in 30 minutes Availability in the Optum Store expands access to this unique testing option amidst a surge of US COVID-19 cases caused by the Omicron variant Lucira's test uniquely offers PCR accuracy and early detection without the 24 hour+ wait for results Lucira... Read More
Lucira Health, Inc. ("Lucira") (Nasdaq: LHDX), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits, today announced preliminary revenue results for the fourth quarter and full year 2021. Preliminary, unaudited revenue for the fourth quarter 2021 is expected to be between $58 million and $60 million, reflecting growth of approximately 300%... Read More
Lucira is the only EUA authorized at-home self-test kit that delivers PCR-quality accuracy and early detectability in a single-use test kit with results in 30 minutes Co-Defend and Co-Protect are leading providers of customized health & safety solutions, and testing & advisory services to Entertainment, Federal, State, and Local governments, Fortune 500 companies, and professional sports teams and leagues Lucira Health, Inc.... Read More
Lucira's tests are the only available at-home self-test kits that deliver PCR-quality accuracy and early detectability in a single-use test kit with results in 30 minutes Current surge of COVID-19 cases caused by the Omicron variant highlights the need for additional at-home testing that can reliably detect early infections and deliver rapid results Lucira Health, Inc. ("Lucira") (Nasdaq: LHDX), a medical technology company... Read More
Lucira assessment confirms COVID-19 Check-It (OTC) and All-In-One (Rx) molecular self-test kits' ability to detect 100% of Omicron variant genome sequences analyzed Lucira assays target viral sequence regions unaffected by the spike protein mutations found in Omicron, Delta and other Variants of Concern Lucira's tests are the only EUA Authorized, at home self-test kits that deliver PCR quality accuracy and early... Read More
Lucira Health, Inc. (Nasdaq: LHDX) ("Lucira Health," "Lucira" or the "Company"), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits, today reported financial results for the third quarter ended September 30, 2021 and provided business updates. Highlights Recorded record-high revenue of $15.0 million for the third quarter of 2021,... Read More
Lucira Health, Inc. ("Lucira Health" or "Lucira") (Nasdaq: LHDX), a medical technology company focusing on the development and commercialization of transformative and innovative infectious disease test kits, announced that its LUCIRA™ CHECK IT COVID-19 Test Kit, a self-administered PCR quality, single-use, at home molecular diagnostic test for COVID-19, is available for purchase by Amazon U.S.-customers. "We are delighted... Read More
Lucira Health, Inc. (“Lucira Health” or “Lucira”), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits, today announced that the company will report third quarter 2021 financial results on, Thursday, November 11, 2021. Lucira’s management will host a conference call and webcast at 1:30 p.m. PT / 4:30 p.m. ET that day to discuss the... Read More
This FDA Emergency Use Authorization (“EUA”) first PCR quality, single-use, COVID-19 at home, self-test kit can again be purchased via the Company’s website Lucira Health, Inc. ("Lucira Health" or "Lucira") (Nasdaq: LHDX), a medical technology company focusing on the development and commercialization of transformative and innovative infectious disease test kits, announced that its LUCIRA™ CHECK IT COVID-19 Test Kit, a... Read More
Lucira Health, Inc. ("Lucira Health" or "Lucira") (Nasdaq: LHDX), a medical technology company focusing on the development and commercialization of transformative and innovative infectious disease test kits, received PSAR approval for its LUCIRA CHECK IT COVID-19 Test Kit by Singapore's Health Sciences Authority. Lucira's test kit provides lab quality molecular results on-the-spot within 30 minutes. Chief Revenue Officer... Read More
Lucira Health, Inc. (“Lucira Health” or “Lucira”) (NASDAQ: LHDX), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits, today commented on the recent recall of the FLOQSwabs by supply partner Copan Italia SPA, or Copan. Copan, who supplies FLOQSwabs included in the LUCIRA COVID-19 All-In-One Test Kit and LUCIRA CHECK IT COVID-19 Test Kit,... Read More
Lucira Health, Inc. (“Lucira Health” or “Lucira”) (NASDAQ: LHDX), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits, today announced operations expert Tony Allen has joined the company as Chief Operations Officer. “Tony has a stellar track record in operations management. We’re delighted that he’s bringing his experience, skill set, and... Read More
Lucira Health, Inc. (“Lucira Health” or “Lucira”) (NASDAQ: LHDX), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits, today announced life science professional Ghazi Kashmolah has joined the company as Chief Quality Officer and Executive Vice President Regulatory Affairs. “Ghazi is a strong addition to Lucira’s executive leadership team,... Read More
EMERYVILLE, Calif., Aug. 12, 2021 (GLOBE NEWSWIRE) -- Lucira Health, Inc. (Nasdaq: LHDX) ("Lucira Health," "Lucira" or the "Company"), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits, today reported financial results for the second quarter ended June 30, 2021. Recent Highlights Recorded record-high revenue of $12.4 million for the... Read More
Lucira Health, Inc. (“Lucira Health” or “Lucira”), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits, today announced that the company will report second quarter 2021 financial results on, Thursday, August 12, 2021. Lucira’s management will host a conference call and webcast at 1:30 p.m. PT / 4:30 p.m. ET that day to discuss the... Read More
Lucira Health, Inc. (Nasdaq: LHDX), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits, today announced medtech veteran Kevin Collins has joined the company as Chief Revenue Officer with global revenue responsibility. Collins began his medical technology career with Lumenis Ltd., a medical equipment and laser technologies company, where... Read More
Lucira Health, Inc. (“Lucira Health” or “Lucira”) (NASDAQ: LHDX), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits, today announced that the company will be participating in the William Blair 41st Annual Growth Stock Conference. Lucira Health’s management is scheduled to participate in the conference on Wednesday, June 2, 2021, at... Read More
Lucira Health, Inc. ("Lucira Health," "Lucira" or the "Company") (NASDAQ: LHDX), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits, today reported financial results for the first quarter ended March 31, 2021. Recent Highlights Received second FDA EUA Authorization for over-the-counter ("OTC") use of the LUCIRA CHECK IT COVID-19 Test... Read More
GreenStockNews
Lucira Health, Inc. (Nasdaq: LHDX), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits, today announced that its LUCIRA™ CHECK IT COVID-19 test kit is now available on Amazon.com in the US. Each LUCIRA CHECK IT test kit provides a PCR... Read More
Lucira Health, Inc. (“Lucira Health” or “Lucira”) (Nasdaq: LHDX), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits, today announced that the company will be participating in the BofA Securities 2021 Virtual Healthcare Conference. Lucira Health’s management is scheduled to participate in the conference on Thursday, May 13, 2021, at 9:30... Read More
Lucira Health, Inc. (“Lucira Health” or “Lucira”) (Nasdaq: LHDX), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits, today announced that the company will report first quarter ended March 31, 2021 financial results on Thursday, May 13, 2021. Lucira’s management will host a conference call and webcast at 1:30 p.m. PT / 4:30 p.m. ET that... Read More
Lucira Health, Inc. (Nasdaq: LHDX), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits, today announced the opening of a new production center in the Dominican Republic by its manufacturing partner Jabil Inc. (NYSE: JBL). The new facility will increase production of the LUCIRA CHECK IT™ COVID-19 test kit during the second quarter of... Read More
GreenStockNews
Lucira Health, Inc. (Nasdaq: LHDX), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits, today announced that Health Canada issued an Authorization with Conditions for the LUCIRA™ CHECK IT COVID-19 test kit. The Authorization with... Read More
GreenStockNews
Lucira Health, Inc. (Nasdaq: LHDX), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits, today announced the U.S. Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for over the counter (OTC) sale of the LUCIRA... Read More
Lucira Health, Inc. (Nasdaq: LHDX), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits, today confirmed it can successfully identify the “double mutant” variant of COVID-19 with its Lucira molecular test kit. The “double mutant” variant was first identified in India on March 24, 2021, and found in California on March 25, 2021, by... Read More
GreenStockNews
Lucira Health, Inc. (Nasdaq: LHDX), today announced that U.S. physicians and healthcare providers can now order Lucira COVID-19 All-In-One Test Kits online from lucirahealth.com . This U.S. made and manufactured product is the first FDA authorized, prescription, molecular diagnostic test for COVID-19 that can be... Read More
Lucira Health, Inc. (“Lucira Health” or “Lucira”), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits, today announced the closing of its upsized initial public offering of 10,350,000 shares of its common stock, which includes 1,350,000 shares sold pursuant to the full exercise by the underwriters of their option to purchase additional... Read More

COPYRIGHT ©2022 GREEN STOCK NEWS